Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Series B Preferred Stock [Member]	Additional Paid-in Capital [Member] Series C Preferred Stock [Member]	Additional Paid-in Capital [Member] Series D Preferred Stock [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Deferred Compensation [Member]
Balance at at Oct. 31, 2017	$ 101,256					$ 1		$ 1,045,203				$ (943,533)		$ (415)	$ (280)	$ 280
Balance at (in shares) at Oct. 31, 2017						5,791,068
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common stock, net of fees	7,129							7,129
Sale of common stock, net of fees (in shares)						476,265
Exercise of warrants	3,326							3,326
Exercise of warrants, (in shares)						216,309
Common stock issued, non-employee compensation	282							282
Common stock issued, non-employee compensation, (in shares)						13,226
Share based compensation	3,238							3,238
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans	660							660
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans, (in shares)						(14,913)
Series C convertible preferred stock conversions				$ 20,220						$ 20,220
Series C convertible preferred stock conversions, (in shares)							1,496,368
Preferred dividends — Series B	(3,200)		$ (3,200)					(3,200)
Series D Preferred stock redemption accretion					$ (2,075)						$ (2,075)
Balance at at Oct. 31, 2018	82,194					$ 1		1,073,463				(990,867)		(403)	(363)	363
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Effect of foreign currency translation	12													12
Adjustment for deferred compensation																83
Adjustment for deferred compensation (in shares)						(5,637)
Adjustment for deferred compensation															(83)
Net loss	(47,334)											(47,334)
Balance at (in shares) at Oct. 31, 2018						7,972,686
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common stock, net of fees	43,666					$ 12		43,654
Sale of common stock, net of fees (in shares)						119,128,677
Common stock issued, non-employee compensation	102							102
Common stock issued, non-employee compensation, (in shares)						29,454
Share based compensation	2,804							2,804
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans	200							200
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans, (in shares)						52,607
Series A warrant exchange, (in shares)						500,000
Series C convertible preferred stock conversions	15,489							15,489
Series C convertible preferred stock conversions, (in shares)				3,914,218		3,914,218
Series C convertible preferred stock adjustment for beneficial conversion feature	6,586							6,586
Series C convertible stock redemption value adjustments	(14,597)							(14,597)
Preferred dividends — Series B			(3,231)						$ (3,231)
Series D convertible preferred stock conversions	31,183					$ 6		31,177
Series D convertible preferred stock conversions, (in shares)						62,040,496
Series D Preferred stock redemption accretion					$ (3,793)						$ (3,793)
Balance at at Oct. 31, 2019	75,737	$ (6,654)				$ 19		1,151,454				(1,075,089)	$ (6,654)	(647)	(466)	466
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Effect of foreign currency translation	(244)													(244)
Adjustment for deferred compensation																103
Adjustment for deferred compensation (in shares)						(29,454)
Adjustment for deferred compensation															(103)
Net loss	$ (77,568)											(77,568)
Balance at (in shares) at Oct. 31, 2019	193,608,684					193,608,684
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common stock, net of fees	$ 171,911					$ 9		171,902
Sale of common stock, net of fees (in shares)						86,307,932
Exercise of warrants	37,060					$ 1		37,059
Exercise of warrants, (in shares)						14,696,320
Common stock issued, non-employee compensation	104							104
Common stock issued, non-employee compensation, (in shares)						58,303
Reclassification of value of share based compensation upon approval of authorized shares for grant	401							401
Share based compensation	1,868							1,868
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans	3							3
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans, (in shares)						49,434
Preferred dividends — Series B			$ (3,331)						$ (3,331)
Balance at at Oct. 31, 2020	194,548					$ 29		$ 1,359,454				(1,164,196)		(739)	(432)	432
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Effect of foreign currency translation	(92)													$ (92)
Adjustment for deferred compensation																$ (34)
Adjustment for deferred compensation (in shares)						(13,915)
Adjustment for deferred compensation															$ 34
Net loss	$ (89,107)											$ (89,107)
Balance at (in shares) at Oct. 31, 2020	294,706,758					294,706,758